Prior treatment with vitamin K2 significantly improves the efficacy of risedronate
Open Access
- 12 March 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Osteoporosis International
- Vol. 20 (11), 1863-1872
- https://doi.org/10.1007/s00198-009-0888-z
Abstract
Prior 8-week treatment with menatetrenone, MK-4, followed by 8-week risedronate prevented the shortcomings of individual drugs and significantly increased the strength of ovariectomized ICR mouse femur compared to the ovariectomized (OVX) controls. Neither MK-4 following risedronate nor the concomitant administration may be recommended because they brought the least beneficial effect. The objective of this study was to determine the best combinatory administration of risedronate at 0.25 mg/kg/day (R) with vitamin K2 at approximately 100 μg MK-4/kg/day (K) to improve strength of osteoporotic mouse bone. Thirteen-week-old ICR mice, ovariectomized at 9-week, were treated for 8 weeks with R, K, or R plus K (R/K), and then, either the treatment was withdrawn (WO) or switched to K or R in the case of R and K. After another 8 weeks, the mice were killed, and mechanical tests and analyses of femur properties by peripheral quantitative computed tomography, microfocus X-ray tube computed tomography, and confocal laser Raman microspectroscopy were carried out. The K to R femur turned out superior in parameters tested such as material properties, bone mineral density, BMC, trabecular structure, and geometry of the cortex. The increased cross-sectional moment of inertia, which occurred after K withdrawal, was prevented by risedronate in K to R. In addition to K to R, some properties of R to WO diaphysis and K to WO epiphysis were significantly better than OVX controls. Prior treatment with MK-4 followed by risedronate significantly increased femur strength in comparison to the OVX controls.Keywords
This publication has 40 references indexed in Scilit:
- Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal womenJournal of Bone and Mineral Metabolism, 2008
- Vitamin K Induces Osteoblast Differentiation through Pregnane X Receptor-Mediated Transcriptional Control of the Msx2 GeneMolecular and Cellular Biology, 2007
- Skeletal Effects of Estrogen Are Mediated by Opposing Actions of Classical and Nonclassical Estrogen Receptor PathwaysJournal of Bone and Mineral Research, 2005
- Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2Journal of Bone and Mineral Metabolism, 2004
- Earliest Mineral and Matrix Changes in Force-Induced Musculoskeletal Disease as Revealed by Raman Microspectroscopic ImagingJournal of Bone and Mineral Research, 2004
- Combination use of vitamin K 2 further increases bone volume and ameliorates extremely low turnover bone induced by bisphosphonate therapy in tail-suspension ratsJournal of Bone and Mineral Metabolism, 2003
- Effect of Vitamin K2 on Three-Dimensional Trabecular Microarchitecture in Ovariectomized RatsJournal of Bone and Mineral Research, 2000
- A PCR Analysis of ERα and ERβ mRNA Abundance in Rats and the Effect of OvariectomyJournal of Bone and Mineral Research, 1999
- Serum vitamin K level and bone mineral density in post‐menopausal womenInternational Journal of Gynecology & Obstetrics, 1997
- Effects of intermittent hPTH(1–34) alone and in combination with 1,25(OH)2d3 or risedronate on endosteal bone remodeling in canine cancellous and cortical boneJournal of Bone and Mineral Research, 1996